MX2021008966A - Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular. - Google Patents

Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular.

Info

Publication number
MX2021008966A
MX2021008966A MX2021008966A MX2021008966A MX2021008966A MX 2021008966 A MX2021008966 A MX 2021008966A MX 2021008966 A MX2021008966 A MX 2021008966A MX 2021008966 A MX2021008966 A MX 2021008966A MX 2021008966 A MX2021008966 A MX 2021008966A
Authority
MX
Mexico
Prior art keywords
increasing
phosphate compounds
tissular
perfusion
inositol phosphate
Prior art date
Application number
MX2021008966A
Other languages
English (en)
Spanish (es)
Inventor
Bestard Joan Perelló
Roca Carolina Salcedo
Mohamad Firas Bassissi
Reynés Miquel David Ferrer
Ferrer María Del Mar Pérez
Original Assignee
Sanifit Therapeutics S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit Therapeutics S A filed Critical Sanifit Therapeutics S A
Publication of MX2021008966A publication Critical patent/MX2021008966A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021008966A 2019-01-30 2020-01-30 Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular. MX2021008966A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382061 2019-01-30
US201962913259P 2019-10-10 2019-10-10
PCT/ES2020/070070 WO2020157362A1 (en) 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion

Publications (1)

Publication Number Publication Date
MX2021008966A true MX2021008966A (es) 2021-11-04

Family

ID=69770927

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008966A MX2021008966A (es) 2019-01-30 2020-01-30 Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular.

Country Status (11)

Country Link
US (2) US20220000889A1 (https=)
EP (1) EP3917535A1 (https=)
JP (2) JP2022521119A (https=)
KR (1) KR20210148078A (https=)
CN (1) CN113365636A (https=)
AU (1) AU2020213713B2 (https=)
BR (1) BR112021014897A2 (https=)
CA (1) CA3130735A1 (https=)
IL (1) IL285084A (https=)
MX (1) MX2021008966A (https=)
WO (1) WO2020157362A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018445164B2 (en) 2018-10-11 2025-05-29 Vifor (International) Ltd. Inositol phosphates for the treatment of ectopic calcification
MX2023005931A (es) * 2020-11-20 2023-08-03 Vifor Int Ag Analogos de hexakisfosfato de inositol para el tratamiento de enfermedades renales asociadas con la calcificacion.
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO2001013933A2 (en) * 1999-08-25 2001-03-01 Gmp Companies, Inc. Agents for the enhanced oxygen delivery in mammals
AU7995600A (en) * 1999-10-05 2001-05-10 Theramed, Inc. Compositions and methods for the incorporation of chemical substances into cells
CA2389236A1 (en) 1999-11-02 2001-05-10 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US20020142995A1 (en) * 2000-08-01 2002-10-03 Nicolau Yves Claude Ammonium salts of hemoglobin allosteric effectors, and uses thereof
WO2002010177A1 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP3678144B2 (ja) 2000-12-22 2005-08-03 ウシオ電機株式会社 フィルム回路基板の周辺露光装置
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
CN105949234B (zh) 2011-09-29 2018-07-10 苏黎世联邦理工学院 用于治疗艰难梭菌感染的药物化合物
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
EA037572B1 (ru) * 2015-12-11 2021-04-15 Этх Цюрих Производные инозитола для применения в патологической кристаллизации
DK3386994T3 (da) 2015-12-11 2020-01-13 Eth Zuerich 4,6-di-(o-thiophosphat)-inositol-1,2,3,5-tetra-o-sulfat mod c. difficile-infektion

Also Published As

Publication number Publication date
CN113365636A (zh) 2021-09-07
AU2020213713B2 (en) 2025-08-21
US20220000889A1 (en) 2022-01-06
CA3130735A1 (en) 2020-08-06
US20230248749A1 (en) 2023-08-10
EP3917535A1 (en) 2021-12-08
AU2020213713A1 (en) 2021-07-22
IL285084A (en) 2021-09-30
JP2022521119A (ja) 2022-04-06
JP2024175025A (ja) 2024-12-17
KR20210148078A (ko) 2021-12-07
BR112021014897A2 (pt) 2021-09-28
WO2020157362A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
ZA202306172B (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
MX2022003984A (es) Compuestos heterociclicos antivirales.
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MY194850A (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
MX2021008966A (es) Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular.
PH12015500313A1 (en) Orally administered medical composition
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
BR112021022216A2 (pt) Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
AR119158A1 (es) Tratamientos de angioedema hereditario
PH12022550790A1 (en) Oral complement factor d inhibitors
MX2026001199A (es) Inhibidores del factor d del complemento para administracion oral
MX2022009032A (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
TN2022000255A1 (en) Pyrrolopyrimidine amines as complement inhibitors
PH12021550170A1 (en) Pharmaceutical dosage form which can be adminitered orally and has modified release
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
ZA202108034B (en) Crystalline salt forms of a kinase inhibitor
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
BR112015012497A2 (pt) combinações farmacêuticas
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
ZA202400679B (en) Dimethyl-substituted thiazololactam compound and use thereof
MX2020009334A (es) Compuestos para tratar la enfermedad de alzheimer.